GlassScriptPhysician profile
Holly Caudill
NPI 1629539325
$1,232.19
in general payments reported to CMS, 2019-2025
21 companies · $536 in 2025
The $536 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.55 · 2023: $327 · 2024: $354 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $154.82 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $137.76 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $137.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $104.54 | 2023-2025 | |
| Pfizer INC. | $87.61 | 2023-2025 | |
| Lilly USA, LLC | $81.63 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Medtronic, INC. | $80.50 | 2025 | Synchromedii |
| Abbvie INC. | $64.08 | 2023-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.20 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $45.68 | 2023 | |
| Exact Sciences Corporation | $42.16 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $41.60 | 2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $33.99 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $33.52 | 2025 | Rexulti |
| Abbott Laboratories | $30.39 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.76 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $19.37 | 2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $19.08 | 2024 | Farxiga |
| Axsome Therapeutics, INC. | $17.90 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.75 | 2024 | Caplyta |
| Insulet Corporation | $14.80 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.